Published in Oncogene on September 14, 2009
Stable isotope labeling with amino acids in cell culture (SILAC)-based quantitative proteomics study of a thyroid hormone-regulated secretome in human hepatoma cells. Mol Cell Proteomics (2011) 0.87
microRNAs 424 and 503 are mediators of the anti-proliferative and anti-invasive action of the thyroid hormone receptor beta. Oncotarget (2014) 0.86
Thyroid hormone receptors promote metastasis of human hepatoma cells via regulation of TRAIL. Cell Death Differ (2012) 0.86
The role of thyroid hormone signaling in the prevention of digestive system cancers. Int J Mol Sci (2013) 0.83
Molecular functions of thyroid hormones and their clinical significance in liver-related diseases. Biomed Res Int (2013) 0.80
Recruitment of the oncoprotein v-ErbA to aggresomes. Mol Cell Endocrinol (2010) 0.78
Mutant thyroid hormone receptors (TRs) isolated from distinct cancer types display distinct target gene specificities: a unique regulatory repertoire associated with two renal clear cell carcinomas. Mol Endocrinol (2011) 0.77
The functional significance of common polymorphisms in zinc finger transcription factors. G3 (Bethesda) (2014) 0.77
A conserved lysine in the thyroid hormone receptor-alpha1 DNA-binding domain, mutated in hepatocellular carcinoma, serves as a sensor for transcriptional regulation. Mol Cancer Res (2010) 0.77
Autoregulatory loop of nuclear corepressor 1 expression controls invasion, tumor growth, and metastasis. Proc Natl Acad Sci U S A (2016) 0.76
Hepatocellular carcinoma: thyroid hormone promotes tumorigenicity through inducing cancer stem-like cell self-renewal. Sci Rep (2016) 0.75
Thyroid hormone suppresses hepatocarcinogenesis via DAPK2 and SQSTM1-dependent selective autophagy. Autophagy (2016) 0.75
Chemotherapy resistance and metastasis-promoting effects of thyroid hormone in hepatocarcinoma cells are mediated by suppression of FoxO1 and Bim pathway. Cell Death Dis (2016) 0.75
Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol (2004) 101.91
Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (2003) 100.88
GenePattern 2.0. Nat Genet (2006) 29.07
Cancer genes and the pathways they control. Nat Med (2004) 24.22
The c-erb-A gene encodes a thyroid hormone receptor. Nature (1987) 10.53
The c-erb-A protein is a high-affinity receptor for thyroid hormone. Nature (1987) 7.06
Physiological and molecular basis of thyroid hormone action. Physiol Rev (2001) 5.69
Protein encoded by v-erbA functions as a thyroid-hormone receptor antagonist. Nature (1989) 4.47
The syndromes of resistance to thyroid hormone. Endocr Rev (1993) 3.70
Thyroid hormone receptors: multiple forms, multiple possibilities. Endocr Rev (1993) 3.70
Structural determinants of nuclear receptor assembly on DNA direct repeats. Nature (1995) 3.32
The mechanism of action of thyroid hormones. Annu Rev Physiol (2000) 2.80
v-erbA oncogene activation entails the loss of hormone-dependent regulator activity of c-erbA. Cell (1990) 2.31
Role of the v-erbA and v-erbB oncogenes of avian erythroblastosis virus in erythroid cell transformation. Cell (1983) 2.08
Multiple mechanisms for regulation of the transcriptional activity of thyroid hormone receptors. Rev Endocr Metab Disord (2000) 1.71
An unliganded thyroid hormone beta receptor activates the cyclin D1/cyclin-dependent kinase/retinoblastoma/E2F pathway and induces pituitary tumorigenesis. Mol Cell Biol (2005) 1.67
Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor. Proc Natl Acad Sci U S A (2006) 1.62
Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival. Cancer Res (2008) 1.57
Nuclear receptor corepressors activate rather than suppress basal transcription of genes that are negatively regulated by thyroid hormone. Mol Cell Biol (1997) 1.52
The biological role and regulation of versican levels in cancer. Cancer Metastasis Rev (2009) 1.51
Identification of naturally occurring dominant negative mutants of thyroid hormone alpha 1 and beta 1 receptors in a human hepatocellular carcinoma cell line. Endocrinology (1996) 1.49
Antiapoptotic effect of serum and glucocorticoid-inducible protein kinase is mediated by novel mechanism activating I{kappa}B kinase. Cancer Res (2005) 1.48
Intracellular receptors use a common mechanism to interpret signaling information at response elements. Genes Dev (1996) 1.46
Molecular and developmental analyses of thyroid hormone receptor function in Xenopus laevis, the African clawed frog. Gen Comp Endocrinol (2005) 1.46
Mechanism of thyroid hormone action. Thyroid (2002) 1.36
Tissue-specific actions of thyroid hormone: insights from animal models. Rev Endocr Metab Disord (2000) 1.35
Molecular basis of resistance to thyroid hormone. Trends Endocrinol Metab (2003) 1.33
Dickkopf-1 antagonizes Wnt signaling independent of beta-catenin in human mesothelioma. Biochem Biophys Res Commun (2004) 1.31
Thyroid hormone receptor mutations and disease: beyond thyroid hormone resistance. Trends Endocrinol Metab (2005) 1.27
Thyroid hormone receptors mutated in liver cancer function as distorted antimorphs. Oncogene (2006) 1.26
Thyroid hormone receptor beta1 acts as a potent suppressor of tumor invasiveness and metastasis. Cancer Res (2009) 1.25
A novel mechanism of action for v-ErbA: abrogation of the inactivation of transcription factor AP-1 by retinoic acid and thyroid hormone receptors. Cell (1991) 1.25
Thyroid hormone action: a binding contract. J Clin Invest (2003) 1.24
P21-activated kinases in human cancer. Cancer Metastasis Rev (2003) 1.23
Functionally impaired TR mutants are present in thyroid papillary cancer. J Clin Endocrinol Metab (2002) 1.23
Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells. Mol Carcinog (1999) 1.21
Expression of mutant thyroid hormone nuclear receptors is associated with human renal clear cell carcinoma. Carcinogenesis (2002) 1.18
Thyroid hormone receptors/THR genes in human cancer. Cancer Lett (2003) 1.17
International Union of Pharmacology. LIX. The pharmacology and classification of the nuclear receptor superfamily: thyroid hormone receptors. Pharmacol Rev (2006) 1.14
v-erbA oncogene function in neoplasia correlates with its ability to repress retinoic acid receptor action. Cell (1991) 1.11
Nuclear receptor recruitment of histone-modifying enzymes to target gene promoters. Vitam Horm (2004) 1.09
Nuclear hormone receptors involved in neoplasia: erb A exhibits a novel DNA sequence specificity determined by amino acids outside of the zinc-finger domain. Mol Cell Biol (1993) 1.08
Silencing of Wnt signaling and activation of multiple metabolic pathways in response to thyroid hormone-stimulated cell proliferation. Mol Cell Biol (2001) 1.06
Essential role of GATA2 in the negative regulation of thyrotropin beta gene by thyroid hormone and its receptors. Mol Endocrinol (2007) 1.06
The thyroid hormone receptor is a suppressor of ras-mediated transcription, proliferation, and transformation. Mol Cell Biol (2004) 1.06
Nonbiased identification of DNA sequences that bind thyroid hormone receptor alpha 1 with high affinity. J Biol Chem (1993) 1.05
Thyroid abnormalities and hepatocellular carcinoma in mice transgenic for v-erbA. EMBO J (1994) 1.02
Dickkopf-1 mediated tumor suppression in human breast carcinoma cells. Breast Cancer Res Treat (2007) 1.01
Thyroid hormone receptor mutations in cancer. Mol Cell Endocrinol (2003) 0.96
Sequence-specific DNA binding by the v-erbA oncogene protein of avian erythroblastosis virus. J Virol (1990) 0.96
V-erbA and c-erbA proteins enhance transcriptional activation by c-jun. Oncogene (1992) 0.94
Thyroid hormone receptor mutations found in renal clear cell carcinomas alter corepressor release and reveal helix 12 as key determinant of corepressor specificity. Mol Endocrinol (2009) 0.93
Corepressor SMRT functions as a coactivator for thyroid hormone receptor T3Ralpha from a negative hormone response element. J Biol Chem (2002) 0.92
Dominant negative activity of mutant thyroid hormone alpha1 receptors from patients with hepatocellular carcinoma. Endocrinology (1997) 0.91
Thyroid hormone modulates apolipoprotein B gene expression in HepG2 cells. Biochem Biophys Res Commun (1992) 0.90
Hormone-dependent repression of the E2F-1 gene by thyroid hormone receptors. Mol Endocrinol (2003) 0.89
A conserved lysine in the estrogen receptor DNA binding domain regulates ligand activation profiles at AP-1 sites, possibly by controlling interactions with a modulating repressor. Nucl Recept (2004) 0.88
Avian erythroleukemia: a model for corepressor function in cancer. Oncogene (2001) 0.88
The rat glucocorticoid receptor mutant K461A differentiates between two different mechanisms of transrepression. J Biol Chem (1997) 0.87
v-erb A, nuclear hormone receptors, and oncogenesis. Biochim Biophys Acta (1992) 0.87
Syndrome of resistance to thyroid hormone: insights into thyroid hormone action. Proc Soc Exp Biol Med (1996) 0.84
Expression and function of thyroid hormone receptor variants in normal and chronically diseased human liver. J Clin Endocrinol Metab (1996) 0.84
Multiple isoforms of thyroid hormone receptor: an analysis of their relative contribution in mediating thyroid hormone action. Nagoya J Med Sci (1998) 0.84
Germline and somatic thyroid hormone receptor mutations in man. J Endocrinol Invest (2003) 0.83
Resistance to thyroid hormone. Clin Lab Med (1993) 0.83
Modulation of expression of RA-regulated genes by the oncoprotein v-erbA. Gene (2008) 0.82
Resistance to thyroid hormone. Ann Intern Med (1996) 0.79
Thyroid hormone receptors and stimulation of angiotensinogen production in HepG2 cells. In Vitro Cell Dev Biol (1991) 0.78
Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell (1997) 8.72
SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor alpha (RARalpha) and PLZF-RARalpha oncoproteins associated with acute promyelocytic leukemia. Proc Natl Acad Sci U S A (1997) 2.75
Site-specific mutagenesis of avian erythroblastosis virus: erb-B is required for oncogenicity. Virology (1983) 2.53
Identification of TRACs (T3 receptor-associating cofactors), a family of cofactors that associate with, and modulate the activity of, nuclear hormone receptors. Mol Endocrinol (1996) 2.02
The product of the avian erythroblastosis virus erbB locus is a glycoprotein. Cell (1983) 1.62
Components of the SMRT corepressor complex exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-RARalpha, and BCL-6. J Biol Chem (1998) 1.61
The SMRT corepressor is regulated by a MEK-1 kinase pathway: inhibition of corepressor function is associated with SMRT phosphorylation and nuclear export. Mol Cell Biol (2000) 1.60
Thyroid hormone resistance syndrome manifests as an aberrant interaction between mutant T3 receptors and transcriptional corepressors. Mol Endocrinol (1997) 1.60
Transcriptional repression by the SMRT-mSin3 corepressor: multiple interactions, multiple mechanisms, and a potential role for TFIIB. Mol Cell Biol (1998) 1.51
Proteins specified by avian erythroblastosis virus: coding region localization and identification of a previously undetected erb-B polypeptide. Proc Natl Acad Sci U S A (1982) 1.36
The structure and synthesis of influenza virus phosphoproteins. J Biol Chem (1981) 1.27
Thyroid hormone receptors mutated in liver cancer function as distorted antimorphs. Oncogene (2006) 1.26
Phosphorylated protein component present in influenza virions. J Virol (1977) 1.24
The membrane glycoprotein encoded by the retroviral oncogene v-erb-B is structurally related to tyrosine-specific protein kinases. Proc Natl Acad Sci U S A (1984) 1.23
Subcellular localization of the v-erb-B protein, the product of a transforming gene of avian erythroblastosis virus. Virology (1984) 1.20
Transcriptional silencing is defined by isoform- and heterodimer-specific interactions between nuclear hormone receptors and corepressors. Mol Cell Biol (1998) 1.16
Leukemia initiated by PMLRARalpha: the PML domain plays a critical role while retinoic acid-mediated transactivation is dispensable. Blood (2000) 1.15
The avian erythroblastosis virus erbA oncogene encodes a DNA-binding protein exhibiting distinct nuclear and cytoplasmic subcellular localizations. J Virol (1988) 1.13
Reconstitution of retinoid X receptor function and combinatorial regulation of other nuclear hormone receptors in the yeast Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (1993) 1.13
v-erbA oncogene function in neoplasia correlates with its ability to repress retinoic acid receptor action. Cell (1991) 1.11
Nuclear hormone receptors involved in neoplasia: erb A exhibits a novel DNA sequence specificity determined by amino acids outside of the zinc-finger domain. Mol Cell Biol (1993) 1.08
Influenza virus proteins: identity, synthesis, and modification analyzed by two-dimensional gel electrophoresis. Proc Natl Acad Sci U S A (1978) 1.08
Structural domains of the avian erythroblastosis virus erbB protein required for fibroblast transformation: dissection by in-frame insertional mutagenesis. J Virol (1986) 1.07
Cooperative formation of high-order oligomers by retinoid X receptors: an unexpected mode of DNA recognition. Proc Natl Acad Sci U S A (1995) 1.05
The erbA oncogene represses the actions of both retinoid X and retinoid A receptors but does so by distinct mechanisms. Mol Cell Biol (1993) 1.04
Transcriptional anti-repression. Thyroid hormone receptor beta-2 recruits SMRT corepressor but interferes with subsequent assembly of a functional corepressor complex. J Biol Chem (1999) 1.02
A conformational switch in nuclear hormone receptors is involved in coupling hormone binding to corepressor release. Mol Cell Biol (1997) 1.02
Signaling by tyrosine kinases negatively regulates the interaction between transcription factors and SMRT (silencing mediator of retinoic acid and thyroid hormone receptor) corepressor. Mol Endocrinol (1998) 1.00
v-erbA and citral reduce the teratogenic effects of all-trans retinoic acid and retinol, respectively, in Xenopus embryogenesis. Development (1993) 0.99
DNA recognition by the aberrant retinoic acid receptors implicated in human acute promyelocytic leukemia. Cell Growth Differ (2001) 0.99
Plasticity of tetramer formation by retinoid X receptors. An alternative paradigm for DNA recognition. J Biol Chem (1997) 0.97
Transmembrane domain of the AEV erb B oncogene protein is not required for partial manifestation of the transformed phenotype. Virology (1987) 0.97
Sequence-specific DNA binding by the v-erbA oncogene protein of avian erythroblastosis virus. J Virol (1990) 0.96
DNA recognition by normal and oncogenic thyroid hormone receptors. Unexpected diversity in half-site specificity controlled by non-zinc-finger determinants. J Biol Chem (1996) 0.95
Arsenic trioxide is a potent inhibitor of the interaction of SMRT corepressor with Its transcription factor partners, including the PML-retinoic acid receptor alpha oncoprotein found in human acute promyelocytic leukemia. Mol Cell Biol (2001) 0.95
Ontogeny of the v-erbA oncoprotein from the thyroid hormone receptor: an alteration in the DNA binding domain plays a role crucial for v-erbA function. J Virol (1991) 0.95
V-erbA and c-erbA proteins enhance transcriptional activation by c-jun. Oncogene (1992) 0.94
The SMRT corepressor is a target of phosphorylation by protein kinase CK2 (casein kinase II). Mol Cell Biochem (2001) 0.94
Transcriptional repression by thyroid hormone receptors. A role for receptor homodimers in the recruitment of SMRT corepressor. J Biol Chem (2001) 0.93
Resistance to thyroid hormone (RTH) syndrome reveals novel determinants regulating interaction of T3 receptor with corepressor. Mol Cell Endocrinol (2000) 0.93
Orientation of the v-erb-B gene product in the plasma membrane. Mol Cell Biol (1986) 0.90
Mapping of functional domains within the v-erb A oncogene protein: the remnants of the hormone binding domain play multiple, vital roles in protein action. Oncogene (1990) 0.86
Phosphorylation of thyroid hormone receptors by protein kinase A regulates DNA recognition by specific inhibition of receptor monomer binding. J Biol Chem (1998) 0.86
Isoform-specific transcriptional regulation by thyroid hormone receptors: hormone-independent activation operates through a steroid receptor mode of co-activator interaction. Mol Endocrinol (2001) 0.83
Mutagenesis of the avian erythroblastosis virus erbB coding region: an intact extracellular domain is not required for oncogenic transformation. J Virol (1986) 0.83
Creation of a chimeric oncogene: analysis of the biochemical and biological properties of v-erbB/src fusion polypeptide. J Virol (1987) 0.83
Functional domains of the v-erbA protein necessary for oncogenesis are required for transcriptional activation in Saccharomyces cerevisiae. Oncogene (1993) 0.82
DNA sequence specificity of the v-erb A oncoprotein/thyroid hormone receptor: role of the P-box and its interaction with more N-terminal determinants of DNA recognition. Mol Endocrinol (1994) 0.80
Reconstitution of thyroid hormone receptor and retinoic acid receptor function in the fission yeast Schizosaccharomyces pombe. Mol Endocrinol (1994) 0.80
Retinoid X and retinoic acid receptors interact with transcription factor II-B by distinct mechanisms. Mol Cell Endocrinol (1997) 0.79
Role of the N terminus in DNA recognition by the v-erb A protein, an oncogenic derivative of a thyroid hormone receptor. Mol Endocrinol (1995) 0.77
Retinoid isomers differ in the ability to induce release of SMRT corepressor from retinoic acid receptor-alpha. J Biol Chem (1999) 0.77
Functional interaction between the two zinc finger domains of the v-erb A oncoprotein. Cell Growth Differ (1992) 0.76